CD8A and neoplasm: In this study of glioblastoma patients treated with adjuvant ADCTA immunotherapy compared to conventional adjuvant therapy, the treatment responsiveness in ADCTA group was found to be strongly associated with a low TIL PD-1+/CD8+ ratio within the glioblastoma tumor.